OVID logo

Ovid Therapeutics (OVID) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

05 May 2017

Indexes:

Not included

Description:

Ovid Therapeutics is a biopharmaceutical company focused on developing treatments for rare neurological disorders. They aim to improve the lives of patients through innovative therapies, particularly for conditions like epilepsy and other central nervous system diseases. Their research combines science and patient needs to create effective solutions.

Events Calendar

Earnings

Next earnings date:

Mar 07, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Mar 08, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

04 Dec '24 HC Wainwright & Co.
Buy
30 Sept '24 HC Wainwright & Co.
Buy
19 Aug '24 HC Wainwright & Co.
Buy
26 July '24 HC Wainwright & Co.
Buy
02 July '24 HC Wainwright & Co.
Buy
18 June '24 HC Wainwright & Co.
Buy
18 June '24 Citigroup
Neutral
18 June '24 BTIG
Buy
18 June '24 B. Riley Securities
Buy
16 May '24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates
Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates
Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates
OVID
zacks.com12 November 2024

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.16 per share a year ago.

Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why
Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why
Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why
OVID
zacks.com20 August 2024

Ovid Therapeutics (OVID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm
Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm
Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm
OVID
accesswire.com18 August 2024

LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm
Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm
Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm
OVID
accesswire.com17 August 2024

LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law Firm
Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law Firm
Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law Firm
OVID
accesswire.com16 August 2024

LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Ovid Therapeutics Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm
Ovid Therapeutics Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm
Ovid Therapeutics Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm
OVID
accesswire.com14 August 2024

LOS ANGELES, CA / ACCESSWIRE / August 14, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
OVID
globenewswire.com13 August 2024

NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today reported business updates and financial results for the second quarter ended June 30, 2024.

Ovid Therapeutics Inc Investors Invited To Join Fraud Investigation With Schall Law Firm
Ovid Therapeutics Inc Investors Invited To Join Fraud Investigation With Schall Law Firm
Ovid Therapeutics Inc Investors Invited To Join Fraud Investigation With Schall Law Firm
OVID
accesswire.com12 August 2024

LOS ANGELES, CA / ACCESSWIRE / August 12, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
OVID
globenewswire.com03 August 2024

NEW YORK, Aug. 03, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ovid Therapeutics Inc. (“Ovid” or the “Company”) (NASDAQ: OVID). Such investors are advised to contact Danielle Peyton at [email protected]  or 646-581-9980, ext. 7980.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
OVID
prnewswire.com01 August 2024

NEW YORK , Aug. 1, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or the "Company") (NASDAQ: OVID). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

FAQ

  • What is the primary business of Ovid Therapeutics?
  • What is the ticker symbol for Ovid Therapeutics?
  • Does Ovid Therapeutics pay dividends?
  • What sector is Ovid Therapeutics in?
  • What industry is Ovid Therapeutics in?
  • What country is Ovid Therapeutics based in?
  • When did Ovid Therapeutics go public?
  • Is Ovid Therapeutics in the S&P 500?
  • Is Ovid Therapeutics in the NASDAQ 100?
  • Is Ovid Therapeutics in the Dow Jones?
  • When was Ovid Therapeutics's last earnings report?
  • When does Ovid Therapeutics report earnings?
  • Should I buy Ovid Therapeutics stock now?

What is the primary business of Ovid Therapeutics?

Ovid Therapeutics is a biopharmaceutical company focused on developing treatments for rare neurological disorders. They aim to improve the lives of patients through innovative therapies, particularly for conditions like epilepsy and other central nervous system diseases. Their research combines science and patient needs to create effective solutions.

What is the ticker symbol for Ovid Therapeutics?

The ticker symbol for Ovid Therapeutics is NASDAQ:OVID

Does Ovid Therapeutics pay dividends?

No, Ovid Therapeutics does not pay dividends

What sector is Ovid Therapeutics in?

Ovid Therapeutics is in the Healthcare sector

What industry is Ovid Therapeutics in?

Ovid Therapeutics is in the Biotechnology industry

What country is Ovid Therapeutics based in?

Ovid Therapeutics is headquartered in United States

When did Ovid Therapeutics go public?

Ovid Therapeutics's initial public offering (IPO) was on 05 May 2017

Is Ovid Therapeutics in the S&P 500?

No, Ovid Therapeutics is not included in the S&P 500 index

Is Ovid Therapeutics in the NASDAQ 100?

No, Ovid Therapeutics is not included in the NASDAQ 100 index

Is Ovid Therapeutics in the Dow Jones?

No, Ovid Therapeutics is not included in the Dow Jones index

When was Ovid Therapeutics's last earnings report?

Ovid Therapeutics's most recent earnings report was on 12 November 2024

When does Ovid Therapeutics report earnings?

The next expected earnings date for Ovid Therapeutics is 7 March 2025

Should I buy Ovid Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions